ITT Institute of Tumours of Tuscany (logo)

Endocrinologia

Azienda Ospedaliera Universitaria Senese
Viale Bracci 1, 53100, Siena
Tel: 0577 585406
Fax. 0577 586187

Nominativo responsabile: Prof. Furio Pacini

Progetti Specifici

  • Grant Regionali AIRC 2003. Optimising the regimen of rhTSH administration for the follow-up and therapy of differentiated thyroid carcinoma.
  • Grant Regionali AIRC 2005. Development of a gene expression-based method for the pre-surgical diagnosis of malignant thyroid disease. Rinnovato per il 2006.
  • MIUR: Ricerche Scientifiche di interesse Nazionale 2003 Chemioterapia del carcinoma scarsamente differenziato della tiroide sotto stimolazione tireotropinica Durata 24 mesi.
  • MIUR: Ricerche Scientifiche di interesse Nazionale 2004 Caratterizzazione di oncogeni e proteine codificate nei carcinomi tiroidei. Durata 24 mesi.
  • MIUR: Ricerche Scientifiche di interesse Nazionale 2005 Modulazione farmacologica in vitro ed in vivo di oncogeni implicati nella tumorigenesi tiroidea. Durata 24 mesi.
  • Ruolo delle sequenze del virus SV40 nel carcinoma tiroideo papillare familiare e degli stimoli autoimmuni cronici nel carcinoma midollare tiroideo. Progetto sottomesso al cofinanziamento MIUR 2006.

Grants

  • Grant Regionali AIRC 2003. Optimising the regimen of rhTSH administration for the follow-up and therapy of differentiated thyroid carcinoma.
  • Grant Regionali AIRC 2005. Development of a gene expression-based method for the pre-surgical diagnosis of malignant thyroid disease. Rinnovato per il 2006.
  • MIUR: Ricerche Scientifiche di interesse Nazionale 2003 Chemioterapia del carcinoma scarsamente differenziato della tiroide sotto stimolazione tireotropinica Durata 24 mesi.
  • MIUR: Ricerche Scientifiche di interesse Nazionale 2004 Caratterizzazione di oncogeni e proteine codificate nei carcinomi tiroidei. Durata 24 mesi.
  • MIUR: Ricerche Scientifiche di interesse Nazionale 2005 Modulazione farmacologica in vitro ed in vivo di oncogeni implicati nella tumorigenesi tiroidea. Durata 24 mesi.
  • Ruolo delle sequenze del virus SV40 nel carcinoma tiroideo papillare familiare e degli stimoli autoimmuni cronici nel carcinoma midollare tiroideo. Progetto sottomesso al cofinanziamento MIUR 2006.

Collaborazioni

  • Azienda Ospedaliera-Universitaria Senese: U.O.C. Anatomia Patologica 1/ U.O.C. Radiologia Universitaria / U.O.C Medicina Nucleare / U.O.C. Genetica Medica / U.O.C. Chirurgia Generale 2/ U.O.C. Otorinolaringoiatria / U.O.C Neurochirurgia Ospedaliera.
  • Azienda Ospedaliera-Universitaria Pisana: Dipartimento di Endocrinologia e Metabolismo/ Divisione di Anatomia Patologica 3 (Prof. F. Basolo)
  • Department of Nuclear Medicine and Endocrine Tumor, Institut Gustave Roussy, Villejuif Cedex, France (Prof. M. Schlumberger)

Pubblicazioni (dal 2001)

  1. Hanscheid H, Lassmann M, Luster M, Thomas SR, Pacini F, Ceccarelli C, Ladenson PW, Wahl RL, Schlumberger M, Ricard M, Driedger A, Kloos RT, Sherman SI, Haugen BR, Carriere V, Corone C, Reiners C. Iodine Biokinetics and Dosimetry in Radioiodine Therapy of Thyroid Cancer: Procedures and Results of a Prospective International Controlled Study of Ablation After rhTSH or Hormone Withdrawal. J Nucl Med. 2006 47:648-654.
  2. Schroeder PR, Haugen BR, Pacini F, Reiners C, Schlumberger M, Sherman SI, Cooper DS, Schuff KG, Braverman LE, Skarulis MC, Davies TF, Mazzaferri EL, Daniels GH, Ross DS, Luster M, Samuels MH, Weintraub BD, Ridgway EC, Ladenson PW. A comparison of short-term changes in health-related quality of life in thyroid carcinoma patients undergoing diagnostic evaluation with recombinant human thyrotropin compared with thyroid hormone withdrawal. J Clin Endocrinol Metab. 2006 91:878-84.
  3. Pacini F, Ladenson PW, Schlumberger M, Driedger A, Luster M, Kloos RT, Sherman S, Haugen B, Corone C, Molinaro E, Elisei R, Ceccarelli C, Pinchera A, Wahl RL, Leboulleux S, Ricard M, Yoo J, Busaidy NL, Delpassand E, Hanscheid H, Felbinger R, Lassmann M, Reiners C. Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. J Clin Endocrinol Metab.2006 91:926-32.
  4. Checchi S, Brilli L, Guarino E, Ciuoli C, Di Cairano G, Mazzucato P, Pacini F. Cyclic Cushing's disease with paradoxical response to dexamethasone. J Endocrinol Invest. 2005 28:741-5.
  5. Pacini F, Schlumberger M, Harmer C, Berg GG, Cohen O, Duntas L, Jamar F, Jarzab B, Limbert E, Lind P, Reiners C, Sanchez Franco F, Smit J, Wiersinga W. Post-surgical use of radioiodine (131I) in patients with papillary and follicular thyroid cancer and the issue of remnantablation:aconsensusreport. Eur J Endocrinol. 2005 153 :651-9.
  6. Guarino E, Tarantini B, Pilli T, Checchi S, Brilli L, Ciuoli C, Di Cairano G, Mazzucato P, Pacini F.Presurgical serum thyroglobulin has no prognostic value in papillary thyroid cancer. Thyroid. 2005 15:1041-5.
  7. Castagna MG, Pinchera A, Marsili A, Giannetti M, Molinaro E, Fierabracci P, Grasso L, Pacini F, Santini F, Elisei R. Influence of human body composition on serum peak thyrotropin (TSH) after recombinant human TSH administration in patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab. 2005 90:4047-50.
  8. Luster M, Lippi F, Jarzab B, Perros P, Lassmann M, Reiners C, Pacini F.rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review. Endocr Relat Cancer. 2005 12: 49-64.
  9. Schlumberger M, Pacini F, Wiersinga WM, Toft A, Smit JW, Sanchez Franco F, Lind P, Limbert E, Jarzab B, Jamar F, Duntas L, Cohen O, Berg G.Follow-up and management of differentiated thyroid carcinoma: a European perspective in clinical practice. Eur J Endocrinol. 2004 151:539-48.
  10. Pacini F, Burroni L, Ciuoli C, Di Cairano G, Guarino E. Management of thyroid nodules: a clinicopathological, evidence-based approach. Eur J Nucl Med Mol Imaging. 2004 31:1443-9.
  11. Puxeddu E, Moretti S, Elisei R, Romei C, Pascucci R, Martinelli M, Marino C, Avenia N, Rossi ED, Fadda G, Cavaliere A, Ribacchi R, Falorni A, Pontecorvi A, Pacini F, Pinchera A, Santeusanio F. BRAF(V599E) mutation is the leading genetic event in adult sporadic papillary thyroid carcinomas. J Clin Endocrinol Metab. 2004 89:2414-20.
  12. Schlumberger M, Berg G, Cohen O, Duntas L, Jamar F, Jarzab B, Limbert E, Lind P, Pacini F, Reiners C, Sanchez Franco F, Toft A, Wiersinga WM. Follow-up of low-risk patients with differentiated thyroid carcinoma: a European perspective. Eur J Endocrinol. 2004 50:105-12.
  13. Elisei R, Bottici V, Luchetti F, Di Coscio G, Romei C, Grasso L, Miccoli P, Iacconi P, Basolo F, Pinchera A, Pacini F. Impact of routine measurement of serum calcitonin on the diagnosis and outcome of medullary thyroid cancer: experience in 10,864 patients with nodular thyroid disorders. J Clin Endocrinol Metab. 2004 89:163-8.
  14. Elisei R, Vivaldi A, Pacini F. Biology and clinical application of the NIS gene. Tumori. 2003 89:523-8. 15.Pacini F. Role of percutaneous ethanol injection in management of nodular lesions of the thyroid gland. J Nucl Med. 2003 44:211-2
  15. Mazzaferri EL, Robbins RJ, Spencer CA, Braverman LE, Pacini F, Wartofsky L, Haugen BR, Sherman SI, Cooper DS, Braunstein GD, Lee S, Davies TF, Arafah BM, Ladenson PW, Pinchera A. A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma.J Clin Endocrinol Metab. 2003 88:1433-41
  16. Chiovato L, Latrofa F, Braverman LE, Pacini F, Capezzone M, Masserini L, Grasso L, Pinchera A. Disappearance of humoral thyroid autoimmunity after complete removal of thyroid antigens. Ann Intern Med. 2003 139:346-51
  17. Pacini F, Capezzone M, Elisei R, Ceccarelli C, Taddei D, Pinchera A. Diagnostic 131-iodine whole-body scan may be avoided in thyroid cancer patients who have undetectable stimulated serum Tg levels after initial treatment. J Clin Endocrinol Metab. 2002 87:1499-501.
  18. Pacini F. Thyroid cancer in children and adolescents. J Endocrinol Invest. 2002 25:572-3
  19. Pacini F Follow-up of differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2002 29 Suppl 2:492-6.
  20. Pacini F, Molinaro E, Castagna MG, Lippi F, Ceccarelli C, Agate L, Elisei R, Pinchera A.Ablation of thyroid residues with 30 mCi (131)I: a comparison in thyroid cancer patients prepared with recombinant human TSH or thyroid hormone withdrawal. J Clin Endocrinol Metab. 2002 87:4063-8
  21. Santini F, Bottici V, Elisei R, Montanelli L, Mazzeo S, Basolo F, Pinchera A, Pacini F. Cytotoxic effects of carboplatinum and epirubicin in the setting of an elevated serum thyrotropin for advanced poorly differentiated thyroid cancer J Clin Endocrinol Metab. 2002 87:4160-5
  22. Miccoli P, Elisei R, Materazzi G, Capezzone M, Galleri D, Pacini F, Berti P, Pinchera A. Minimally invasive video-assisted thyroidectomy for papillary carcinoma: a prospective study of its completeness.Surgery.2002 132:1070-3
  23. Pacini F, Molinaro E, Lippi F, Castagna MG, Agate L, Ceccarelli C, Taddei D, Elisei R, Capezzone M, Pinchera A. Prediction of disease status by recombinant human TSH-stimulated serum Tg in the postsurgical follow-up of differentiated thyroid carcinoma.. J Clin Endocrinol Metab. 2001 86:5686-90.
  24. Brandi ML, Gagel RF, Angeli A, Bilezikian JP, Beck-Peccoz P, Bordi C, Conte-Devolx B, Falchetti A, Gheri RG, Libroia A, Lips CJ, Lombardi G, Mannelli M, Pacini F, Ponder BA, Raue F, Skogseid B, Tamburrano G, Thakker RV, Thompson NW, Tomassetti P, Tonelli F, Wells SA Jr, Marx SJ.Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab. 2001 86:5658-71
  25. Basolo F, Molinaro E, Agate L, Pinchera A, Pollina L, Chiappetta G, Monaco C, Santoro M, Fusco A, Miccoli P, Elisei R, Capezzone M, Pacini F. RET protein expression has no prognostic impact on the long-term outcome of papillary thyroid carcinoma Eur J Endocrinol. 2001 145:599-604.
  26. Pacini F, Elisei R, Capezzone M, Miccoli P, Molinaro E, Basolo F, Agate L, Bottici V, Raffaelli M, Pinchera Contralateral papillary thyroid cancer is frequent at completion thyroidectomy with no difference in low- and high-risk patients.Thyroid.200111:877-81
  27. Pacini F, Agate L, Elisei R, Capezzone M, Ceccarelli C, Lippi F, Molinaro E, Pinchera A Outcome of differentiated thyroid cancer with detectable serum Tg and negative diagnostic (131)I whole body scan: comparison of patients treated with high (131)I activities versus untreated patients J Clin Endocrinol Metab. 2001 86:4092-7
  28. Lippi F, Capezzone M, Angelini F, Taddei D, Molinaro E, Pinchera A, Pacini F. Radioiodine treatment of metastatic differentiated thyroid cancer in patients on L-thyroxine, using recombinant human TSH.Eur J Endocrinol. 2001 144:5-11
  29. Ceccarelli C, Bencivelli W, Morciano D, Pinchera A, Pacini F 131I therapy for differentiated thyroid cancer leads to an earlier onset of menopause: results of a retrospective study. J Clin Endocrinol Metab. 2001 86:3512-5.
  30. Elisei R, Romei C, Vorontsova T, Cosci B, Veremeychik V, Kuchinskaya E, Basolo F, Demidchik EP, Miccoli P, Pinchera A, Pacini F. RET/PTC rearrangements in thyroid nodules: studies in irradiated and not irradiated, malignant and benign thyroid lesions in children and adults. J Clin Endocrinol Metab. 2001 86:3211-6.
  31. Oliynyk V, Epshtein O, Sovenko T, Tronko M, Elisei R, Pacini F, Pinchera A. Post-surgical ablation of thyroid residues with radioiodine in Ukrainian children and adolescents affected by post-Chernobyl differentiated thyroid cancer. J Endocrinol Invest. 2001 24:445-7.